These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 19542250)

  • 1. A feasibility study of sequential doublet chemotherapy comprising carboplatin-doxorubicin and carboplatin-paclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma.
    Ang JE; Shah RN; Everard M; Keyzor C; Coombes I; Jenkins A; Thomas K; A'Hern R; Jones RL; Blake P; Gabra H; Hall G; Gore ME; Kaye SB
    Ann Oncol; 2009 Nov; 20(11):1787-93. PubMed ID: 19542250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carboplatin and nonpegylated liposomal doxorubicin in primary advanced or recurrent endometrial cancer: a phase 2 trial conducted by AGO Austria.
    Volgger B; Zeimet AG; Reinthaller A; Petru E; Schauer C; Klein M; Sevelda-Schwarzgruber U; Bogner G; Wolfram G; Marth C
    Int J Gynecol Cancer; 2015 Feb; 25(2):257-62. PubMed ID: 25611899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination chemotherapy with carboplatin, paclitaxel and pegylated liposomal doxorubicin for advanced or recurrent carcinosarcoma of the uterus: clinical experience of a single institution.
    Pectasides D; Pectasides E; Papaxoinis G; Xiros N; Sykiotis C; Papachristodoulou A; Tountas N; Panayiotides J; Economopoulos T
    Gynecol Oncol; 2008 Sep; 110(3):299-303. PubMed ID: 18602677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Weekly low-dose paclitaxel and carboplatin in the treatment of advanced or recurrent cervical and endometrial cancer.
    Secord AA; Havrilesky LJ; Carney ME; Soper JT; Clarke-Pearson DL; Rodriguez GC; Berchuck A
    Int J Clin Oncol; 2007 Feb; 12(1):31-6. PubMed ID: 17380438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Weekly paclitaxel-carboplatin regimen in patients with primary advanced or recurrent endometrial carcinoma.
    Vandenput I; Vergote I; Neven P; Amant F
    Int J Gynecol Cancer; 2012 May; 22(4):617-22. PubMed ID: 22426408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Efficacy of Low-Dose Paclitaxel Added to Combination Chemotherapy of Carboplatin and Gemcitabine or Pegylated Liposomal Doxorubicin.
    Nagao S; Iwasa N; Kurosaki A; Nishikawa T; Hanaoka T; Hasegawa K; Fujiwara K
    Int J Gynecol Cancer; 2016 Mar; 26(3):443-8. PubMed ID: 26807640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pilot trial of TAC (paclitaxel, doxorubicin, and carboplatin) chemotherapy with filgastrim (r-metHuG-CSF) support followed by radiotherapy in patients with "high-risk" endometrial cancer.
    Duska LR; Berkowitz R; Matulonis U; Muto M; Goodman A; McIntyre JF; Klein A; Atkinson T; Seiden MV; Campos S
    Gynecol Oncol; 2005 Jan; 96(1):198-203. PubMed ID: 15589601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pilot study of combination chemotherapy with paclitaxel, pirarubicin, and carboplatin (TPC) for endometrial carcinoma.
    Hongo A; Kusumoto T; Nakamura K; Seki N; Kodama J; Hiramatsu Y
    Int J Clin Oncol; 2010 Oct; 15(5):476-83. PubMed ID: 20526888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carboplatin plus paclitaxel in the treatment of advanced or recurrent endometrial carcinoma.
    Michener CM; Peterson G; Kulp B; Webster KD; Markman M
    J Cancer Res Clin Oncol; 2005 Sep; 131(9):581-4. PubMed ID: 15959825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of advanced or recurrent endometrial carcinoma with doxorubicin in patients progressing after paclitaxel/carboplatin: Memorial Sloan-Kettering Cancer Center experience from 1995 to 2009.
    Makker V; Hensley ML; Zhou Q; Iasonos A; Aghajanian CA
    Int J Gynecol Cancer; 2013 Jun; 23(5):929-34. PubMed ID: 23598889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paclitaxel and carboplatin with amifostine in advanced, recurrent, or refractory endometrial adenocarcinoma: a phase II study of the Southwest Oncology Group.
    Scudder SA; Liu PY; Wilczynski SP; Smith HO; Jiang C; Hallum AV; Smith GB; Hannigan EV; Markman M; Alberts DS;
    Gynecol Oncol; 2005 Mar; 96(3):610-5. PubMed ID: 15721401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study.
    Powell MA; Filiaci VL; Rose PG; Mannel RS; Hanjani P; Degeest K; Miller BE; Susumu N; Ueland FR
    J Clin Oncol; 2010 Jun; 28(16):2727-31. PubMed ID: 20421537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salvage chemotherapy in recurrent platinum-resistant or refractory epithelial ovarian cancer with Carboplatin and distearoylphosphatidylcholine pegylated liposomal Doxorubicin (lipo-dox®).
    Khemapech N; Oranratanaphan S; Termrungruanglert W; Lertkhachonsuk R; Vasurattana A
    Asian Pac J Cancer Prev; 2013; 14(3):2131-5. PubMed ID: 23679331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel-long-term follow-up.
    Sorbe B; Andersson H; Boman K; Rosenberg P; Kalling M
    Int J Gynecol Cancer; 2008; 18(4):803-8. PubMed ID: 17944917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iniparib plus paclitaxel and carboplatin as initial treatment of advanced or recurrent uterine carcinosarcoma: a Gynecologic Oncology Group Study.
    Aghajanian C; Sill MW; Secord AA; Powell MA; Steinhoff M
    Gynecol Oncol; 2012 Sep; 126(3):424-7. PubMed ID: 22634397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment with paclitaxel plus carboplatin, alone or with irradiation, of advanced or recurrent endometrial carcinoma.
    Arimoto T; Nakagawa S; Yasugi T; Yoshikawa H; Kawana K; Yano T; Taketani Y
    Gynecol Oncol; 2007 Jan; 104(1):32-5. PubMed ID: 16996113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Feasibility study of combination chemotherapy with paclitaxel, doxorubicin and cisplatin without prophylactic granulocyte colony-stimulating factor injection for intermediate-to-high risk or recurrent endometrial cancer.
    Nagao S; Nishikawa T; Hanaoka T; Kurosaki A; Iwasa N; Hasegawa K; Fujiwara K
    Jpn J Clin Oncol; 2014 Nov; 44(11):1040-4. PubMed ID: 25183770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Taxane Plus Platinum Regimens vs Doxorubicin Plus Cisplatin as Adjuvant Chemotherapy for Endometrial Cancer at a High Risk of Progression: A Randomized Clinical Trial.
    Nomura H; Aoki D; Michimae H; Mizuno M; Nakai H; Arai M; Sasagawa M; Ushijima K; Sugiyama T; Saito M; Tokunaga H; Matoda M; Nakanishi T; Watanabe Y; Takahashi F; Saito T; Yaegashi N;
    JAMA Oncol; 2019 Jun; 5(6):833-840. PubMed ID: 30896757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carboplatin and paclitaxel in advanced or metastatic endometrial cancer.
    Pectasides D; Xiros N; Papaxoinis G; Pectasides E; Sykiotis C; Koumarianou A; Psyrri A; Gaglia A; Kassanos D; Gouveris P; Panayiotidis J; Fountzilas G; Economopoulos T
    Gynecol Oncol; 2008 May; 109(2):250-4. PubMed ID: 18299146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pilot study of paclitaxel and carboplatin for recurrent ovarian cancer.
    Adachi S; Ogasawara T; Ito K; Koyama M; Nagano T; Suzuki A; Yamada T; Nakata Y; Ozawa M
    Oncol Rep; 2001; 8(2):285-8. PubMed ID: 11182041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.